| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 08/02/2006 | EP1684769A2 Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone |
| 08/02/2006 | EP1684768A2 Methods of treating eczema |
| 08/02/2006 | EP1684764A2 Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |
| 08/02/2006 | EP1684762A2 Urea derivatives as kinase modulators |
| 08/02/2006 | EP1684759A2 4-phenyl piperdine sulfonyl glycine transporter inhibitors |
| 08/02/2006 | EP1684758A2 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
| 08/02/2006 | EP1684748A2 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrozol-3-one choline |
| 08/02/2006 | EP1684744A2 Pyrrolidine and piperidine derivatives as factor xa inhibitors |
| 08/02/2006 | EP1684741A2 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders |
| 08/02/2006 | EP1684735A2 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| 08/02/2006 | EP1684724A2 Enhanced drug delivery |
| 08/02/2006 | EP1684712A2 Combination drug therapy to treat obesity |
| 08/02/2006 | EP1684706A2 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter |
| 08/02/2006 | EP1684705A2 Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties |
| 08/02/2006 | EP1684704A2 Compositions and methods for increasing hdl and hdl-2b levels |
| 08/02/2006 | EP1684703A2 Methods and compositions for treating mcp-1 related pathologies |
| 08/02/2006 | EP1684702A2 Use of 2-thia-dibenzo(e,h) azulenes for the treatment and prevention of central nervous system diseaes and disorders |
| 08/02/2006 | EP1684696A2 Electrically activated alteration of body tissue stiffness for breathing disorders |
| 08/02/2006 | EP1684695A2 Systems and methods for measuring tear film osmolarity |
| 08/02/2006 | EP1684694A2 Akt protein kinase inhibitors |
| 08/02/2006 | EP1684692A2 Pigment epithelium-derived factor, novel biological activity and methods of use |
| 08/02/2006 | EP1684691A2 Oral delivery system and method for making same |
| 08/02/2006 | EP1684690A2 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
| 08/02/2006 | EP1684689A2 Extended release venlafaxine formulation |
| 08/02/2006 | EP1684682A2 Reduction of unintended use of transdermal devices |
| 08/02/2006 | EP1420815B1 Beta-amyloid-analogue - t-cell epitop vaccine |
| 08/02/2006 | EP1073637B1 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases |
| 08/02/2006 | CN1813061A Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| 08/02/2006 | CN1812995A Industrially scalable nucleoside synthesis |
| 08/02/2006 | CN1812968A Polymorphic form a of 4-{6-acetyl-3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy}-2-propylphenoxy}butyric acid |
| 08/02/2006 | CN1812963A N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| 08/02/2006 | CN1812952A Color stabilization of hydroquinone hydroxyethyl ether products |
| 08/02/2006 | CN1812766A Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds |
| 08/02/2006 | CN1812753A Drug releasing biodegradable fiber for delivery of therapeutics |
| 08/02/2006 | CN1810822A 2-aminocarbonyl-9h-purine derivatives |
| 08/02/2006 | CN1810802A 3-substituted-4-pyrimidone derivatives |
| 08/01/2006 | US7084252 receptor for a satiety factor, which is involved in body weight homeostasis |
| 08/01/2006 | US7084168 Indoline derivatives |
| 08/01/2006 | US7084124 Antidiabetic agents; insulin resistance |
| 08/01/2006 | US7083814 Antiviral substances from plant cuticular and epicuticular material |
| 08/01/2006 | US7083799 No-synthase inhibitors |
| 08/01/2006 | US7083787 Induce immunology response; administering yeast vehicle and antigen |
| 08/01/2006 | US7083781 Film forming polymers, methods of use, and devices and applications thereof |
| 08/01/2006 | CA2285407C Dosage forms comprising separate portions of r- and s-enantiomers |
| 08/01/2006 | CA2255668C Purified extract of harpagophytum procumbens and/or harpagophytum zeyheri dence, process for its production and its use |
| 08/01/2006 | CA2192456C Pyridylbisphosphonates for use as a therapeutical agent |
| 07/27/2006 | WO2005051304A3 Akt protein kinase inhibitors |
| 07/27/2006 | WO2005048954A3 Continuous process for producing hydroxyazapirones by oxidation |
| 07/27/2006 | WO2005020902A3 Compositions and methods for treating and diagnosing irritable bowel syndrome |
| 07/27/2006 | WO2005013906A3 pH-RESPONSIVE FILM FOR INTRAVAGINAL DELIVERY OF A BENEFICIAL AGENT |
| 07/27/2006 | WO2005002516A9 Leukocyte internalized peptide-drug conjugates |
| 07/27/2006 | WO2004110339A3 Method for selective targeting of apoptotic cells and small molecule ligands used thereof |
| 07/27/2006 | WO2004091517A3 Conjugates comprising human il-18 and substitution mutants thereof |
| 07/27/2006 | WO2004091479A3 Gene amplification and overexpression in cancer |
| 07/27/2006 | WO2004073620A3 The selective and specific preparation of discrete peg compounds |
| 07/27/2006 | WO2004064762A9 Novel cocrystallization |
| 07/27/2006 | WO2004019875A3 Non-invasive methods to identify agents for treating pain |
| 07/27/2006 | US20060168668 Phosphodiesterase 2a and methods of use |
| 07/27/2006 | US20060167271 Purified compounds that inhibit intracellular alphax4/paxillin binding |
| 07/27/2006 | US20060167234 a portion of orally administered prodrug remains in prodrug form (i.e., the oligomer remains attached), protecting the polypeptide through the digestive tract; traverses the wall of the digestive tract and enters into the blood stream; and/or converted in the system |
| 07/27/2006 | US20060166980 New oxabispidine compounds useful in the treatment of cardiac arrhythmias |
| 07/27/2006 | US20060166979 for prophylaxis and treatment of atrial and ventricular arrhythmias |
| 07/27/2006 | US20060166972 Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| 07/27/2006 | US20060166957 Methods of treating obesity and related disorders using tellurium selenium compounds |
| 07/27/2006 | US20060166912 Use of cytochrome p450 enzyme cyp2w1 as a drug target for cancer theraphy |
| 07/27/2006 | US20060166865 A modified nucleoside comprising a purine ring for treating viral infections |
| 07/27/2006 | US20060166213 Novel compositions and methods in cancer |
| 07/27/2006 | US20060166212 Breast specific protein expressed in cancer and methods of use thereof |
| 07/27/2006 | US20060165823 Topical delivery agents and methods for making and using therm |
| 07/27/2006 | US20060165792 Controlled release oxycodone compositions |
| 07/27/2006 | US20060165791 Oral dosage form prepared by forming granules comprising oxycodone hydrochloride, alkyl cellulose and polymethacrylate, and drying said granules; improving efficiency and quality of pain management |
| 07/27/2006 | US20060165709 stimulate T cytotoxic lymphocytes in a mammal |
| 07/27/2006 | US20060165652 Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| 07/27/2006 | US20060165649 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| 07/27/2006 | US20060165599 Near infrared imaging agent |
| 07/27/2006 | US20060165598 Using water soluble dyes; contrast media for fluorescence |
| 07/27/2006 | US20060165596 Method and apparatus for noninvasively evaluating endothelial function |
| 07/26/2006 | EP1682682A2 Compositions and methods for modulating c-rel-dependent cytokine production |
| 07/26/2006 | EP1682606A2 Anion-binding polymers and uses thereof |
| 07/26/2006 | EP1682544A2 Hydroxylamine substituted imidazo ring compounds |
| 07/26/2006 | EP1682534A2 Pyrimidin-4-one compounds, compositions, and methods |
| 07/26/2006 | EP1682504A2 Hydroxy piperidine derivatives to treat gaucher disease |
| 07/26/2006 | EP1682173A2 Listeria-based epha2 vaccines |
| 07/26/2006 | EP1682172A2 Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis |
| 07/26/2006 | EP1682171A2 Compositions and methods of treating neurological diseases |
| 07/26/2006 | EP1682143A2 Combinations comprising an hsp90 inhibitor and a phophodiesterase inhibitor for treating or preventing neoplasia |
| 07/26/2006 | EP1682142A2 M3 muscarinic acetylcholine receptor antagonists |
| 07/26/2006 | EP1682138A2 Heterocyclic inhibitors of mek and methods of use thereof |
| 07/26/2006 | EP1682134A2 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| 07/26/2006 | EP1682128A2 Process and formulation containing epothilones and analogs thereof |
| 07/26/2006 | EP1682120A2 Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 07/26/2006 | EP1682115A2 Hif-1 inhibitors and methods of use thereof |
| 07/26/2006 | EP1682106A2 Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes |
| 07/26/2006 | EP1682105A2 N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity |
| 07/26/2006 | EP1682094A2 Multilayer dosage form comprising a matrix that influences release of a modulatory substance |
| 07/26/2006 | EP1682085A2 Variable appearance tissue markings |
| 07/26/2006 | EP1682082A2 Electromagnetic field regulating compositions |
| 07/26/2006 | EP1682077A2 Dialysates and methods and systems related thereto |
| 07/26/2006 | EP1682076A2 Inhibitors of coronavirus protease and methods of use thereof |
| 07/26/2006 | EP1682074A2 Compositions and methods for healthy pregnancy |